AllianceBernstein (AB) – Company Press Releases
-
AB to Report First Quarter 2024 Results on April 25, 2024
-
AB Announces March 31, 2024 Assets Under Management
-
SOCIETE GENERALE AND ALLIANCEBERNSTEIN ANNOUNCE THE OFFICIAL LAUNCH OF BERNSTEIN, A NEW LEADER IN CASH EQUITIES & RESEARCH
-
AB Announces February 29, 2024 Assets Under Management
-
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
-
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
-
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
-
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
-
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
-
AB Announces January 31, 2024 Assets Under Management
-
Seth Bernstein, President and CEO, to Participate in the Bank of America 2024 Financial Services Conference on February 21st, 2024
-
ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES FOURTH QUARTER RESULTS
-
Bernstein Private Wealth Management Announces Expansion of Ultrahigh-Net-Worth Platform
-
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
-
AB to Report Fourth Quarter 2023 Results on February 6, 2024
-
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
-
AB Announces December 31, 2023 Assets Under Management
-
Jackie Marks Joins AllianceBernstein as Chief Financial Officer
-
AllianceBernstein Launches Five New Active ETFs
-
AllianceBernstein Announces Global Head of Investments
-
AB Announces November 30, 2023 Assets Under Management
-
AllianceBernstein Announces Launch of NAV Lending Strategy
-
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
-
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
-
Seth Bernstein, President and CEO, to Participate in the Goldman Sachs 2023 US Financial Services Conference on December 5th, 2023
-
AB Announces October 31, 2023 Assets Under Management
-
ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES THIRD QUARTER RESULTS
-
AB to Report Third Quarter 2023 Results on October 26, 2023
-
AB Announces September 30, 2023 Assets Under Management
-
Erik Bass appointed as Head of Investor Relations for Equitable Holdings
-
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
-
AllianceBernstein Launches AB US Large Cap Strategic Equities ETF (LRGC) on NYSE Arca
-
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
-
AB Announces August 31, 2023 Assets Under Management
-
AllianceBernstein Announces 2022 Schedule K-3 is Now Available Online for Unitholders
-
AB Announces July 31, 2023 Assets Under Management
-
AB CarVal announces final close of CVI Clean Energy Fund II
-
ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES SECOND QUARTER RESULTS
-
AB to Report Second Quarter 2023 Results on July 27, 2023
-
AB Announces June 30, 2023 Assets Under Management
-
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
-
Bernstein Private Wealth Management Launches Bernstein Philanthropic Impact Fund in Partnership with National Philanthropic Trust
-
AB Announces May 31, 2023 Assets Under Management
-
AllianceBernstein Releases Research Evaluating Lifetime Income Solutions for Defined Contribution Plans
-
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
-
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
-
AllianceBernstein Launches AB High Yield ETF (HYFI) on NYSE Arca
-
Equitable Holdings Announces New Financial Guidance at 2023 Investor Day
-
AB Announces April 30, 2023 Assets Under Management
-
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
Back to AB Stock Lookup
